Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Merestinib Monotherapy or in Combination With Other Anti-Cancer Agents in Japanese Patients With Advanced and/or Metastatic Cancer

NCT03027284 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT03027284
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03027284 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Merestinib Monotherapy or in Combination With Other Anti-Cancer Agents in Japanese Patients With Advanced and/or Metastatic Cancer
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Completed
Start date
February 3, 2017
Completion date
March 17, 2020
Enrollment
19 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, biliary tract carcinoma, cholangiocarcinoma, gall bladder carcinoma, metastatic cancer, non-hodgkin's lymphoma, solid tumor